Big Stakes In Lilly Patent Battle: How Broadly Can Patent Claims Be Written?
Executive Summary
As Lilly and Ariad get back in the ring for another round in a major patent battle, those on the sidelines are closely watching the match as it could determine how broadly patent claims may be written. At issue is the question of what constitutes an adequate description of an invention
You may also be interested in...
Biotech Inventions May Be More Easily Deemed Obvious Under Court Ruling
An appeals court ruling that limits the patenting of DNA sequences could have negative repercussions for the industry
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.